Medication info
Valsartan 80 mg Tablet

Valsartan 80 mg Tablet

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Iksu Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201601151 · Approved 2016.02.29 · Insurance code 658501860

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. If possible, take it at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be added. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with intravascular volume depletion (e.g., patients receiving high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. Consider reducing the diuretic dose when administered concomitantly. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, depending on patient tolerability. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed 80 mg of this medicine per day. If administering 80 mg or more per day, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Iksu Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular contractility dysfunction
View approved original text

This medication helps in controlling blood pressure in patients with essential hypertension and is used in heart failure patients (NYHA Class II to IV) who are intolerant to ACE inhibitors. It is also effective in reducing the risk of death in stable patients with left ventricular dysfunction or decreased contractility after myocardial infarction. This drug plays an important role in the management of hypertension and heart failure, as well as in the prevention of complications after myocardial infarction, improving the patient's health status.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. If possible, take it at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be added. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with intravascular volume depletion (e.g., patients receiving high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. Consider reducing the diuretic dose when administered concomitantly. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, depending on patient tolerability. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed 80 mg of this medicine per day. If administering 80 mg or more per day, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the 2nd and 3rd trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, and women who are breastfeeding should not take this medication. Patients with severely impaired liver function or cirrhosis should not use this medication safely. Patients who have had hypersensitivity to this medication or have experienced allergic reactions such as angioedema with similar medications should not take it. Patients with severely impaired kidney function or certain kidney diseases should also not take this medication. Elderly patients or those with high potassium levels or weakened liver function should be cautious when taking this medication, and dose adjustments may be necessary. Patients with heart disease or cerebrovascular disease should be careful to prevent blood pressure from dropping too low. Low blood pressure may occur upon initial use of this medication, so patients, especially those with fluid or sodium depletion, should be monitored while gradually increasing the dose. When used in conjunction with other antihypertensive medications or diuretics, blood pressure, kidney function, and electrolyte levels should be frequently checked. Caution should be taken when used with potassium-sparing diuretics or potassium supplements as it may lead to dangerously high potassium levels in the blood. Taking this medication with non-steroidal anti-inflammatory drugs (NSAIDs) may reduce blood pressure control and worsen kidney function, so caution is needed. This medication can cause dizziness or drowsiness, so care should be taken when driving or operating machinery. In the event of an overdose, symptoms such as low blood pressure, decreased consciousness, and shock may occur, and immediate emergency treatment is required. The safety and efficacy of this medication in children have not been established, and its use is not recommended. This medication should be stored out of reach of children, and transfer to other containers should be avoided.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is important to keep it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.